香港股市 已收市
  • 恒指

    21,859.79
    -137.10 (-0.62%)
     
  • 國指

    7,666.88
    -27.76 (-0.36%)
     
  • 上證綜指

    3,398.62
    +37.10 (+1.10%)
     
  • 道指

    31,029.31
    +82.32 (+0.27%)
     
  • 標普 500

    3,818.83
    -2.72 (-0.07%)
     
  • 納指

    11,177.89
    -3.65 (-0.03%)
     
  • Vix指數

    29.45
    +1.09 (+3.84%)
     
  • 富時100

    7,171.16
    -141.16 (-1.93%)
     
  • 紐約期油

    109.35
    -0.43 (-0.39%)
     
  • 金價

    1,823.40
    +5.90 (+0.32%)
     
  • 美元

    7.8459
    -0.0008 (-0.01%)
     
  • 人民幣

    0.8527
    -0.0007 (-0.08%)
     
  • 日圓

    0.0574
    +0.0002 (+0.28%)
     
  • 歐元

    8.1627
    -0.0282 (-0.34%)
     
  • Bitcoin

    19,232.25
    -810.43 (-4.04%)
     
  • CMC Crypto 200

    412.28
    -27.39 (-6.23%)
     

Zymergen Highlights Early Results From Work On Potential COVID-19 Drug Candidate

  • 噢!
    發生錯誤。
    請稍後再試一次。
·1 分鐘文章
在這篇文章中:
  • 噢!
    發生錯誤。
    請稍後再試一次。

Zymergen Inc (NASDAQ: ZY) announced early results from its work on infectious disease, discovering several potential novel hits against malaria, tuberculosis, and COVID-19 targets.

  • Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow.

  • The multi-target infectious disease program is supported by a Bill & Melinda Gates Foundation grant, enabling Zymergen to identify novel hits for all three target pathogens.

  • For PfAPP, Zymergen has already identified over 200 molecules with better docking scores than the current molecule, apstatin.

  • Docking scores are well-accepted in the industry for virtual screening campaigns, and the best hits are now being moved into validation testing with global partners.

  • Zymergen will oversee all validation.

  • Price Action: ZY shares closed 0.62% higher at $3.25 during after-hours trading on Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

我們致力為用戶建立安全而有趣的平台,讓他們與志同道合的用戶聯繫交流。為改善我們的社群體驗,我們暫時停用文章留言功能